Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Change in Account Payables: 2019-2025

Historic Change in Account Payables for C4 Therapeutics (CCCC) over the last 6 years, with Sep 2025 value amounting to -$885,000.

  • C4 Therapeutics' Change in Account Payables fell 250.00% to -$885,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$172,000, marking a year-over-year decrease of 176.11%. This contributed to the annual value of -$119,000 for FY2024, which is 143.59% down from last year.
  • According to the latest figures from Q3 2025, C4 Therapeutics' Change in Account Payables is -$885,000, which was down 157.69% from $1.5 million recorded in Q2 2025.
  • In the past 5 years, C4 Therapeutics' Change in Account Payables ranged from a high of $1.5 million in Q2 2025 and a low of -$2.0 million during Q1 2021.
  • Moreover, its 3-year median value for Change in Account Payables was -$138,000 (2023), whereas its average is $14,364.
  • Within the past 5 years, the most significant YoY rise in C4 Therapeutics' Change in Account Payables was 314.55% (2025), while the steepest drop was 454.40% (2025).
  • Quarterly analysis of 5 years shows C4 Therapeutics' Change in Account Payables stood at $760,000 in 2021, then plummeted by 241.58% to -$1.1 million in 2022, then soared by 115.71% to $169,000 in 2023, then crashed by 204.14% to -$176,000 in 2024, then tumbled by 250.00% to -$885,000 in 2025.
  • Its Change in Account Payables was -$885,000 in Q3 2025, compared to $1.5 million in Q2 2025 and -$645,000 in Q1 2025.